🇺🇸 FDA
Patent

US 8623371

Targeting poly-gama-glutamic acid to treat Staphylococcus epidermidis and related infections

granted A61KA61K2039/6037A61K2039/6056

Quick answer

US patent 8623371 (Targeting poly-gama-glutamic acid to treat Staphylococcus epidermidis and related infections) held by The United States of America as Represented by the Secretary of the Department of Health and Human Services expires Mon Jan 02 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America as Represented by the Secretary of the Department of Health and Human Services
Grant date
Tue Jan 07 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 02 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K2039/6037, A61K2039/6056, A61K2039/6081, A61K39/085